Xilio Therapeutics, Inc. Profile Avatar - Palmy Investing

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Pha…

Biotechnology
US, Waltham [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Xilio Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Xilio Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Xilio Therapeutics, Inc..

End of XLO's Analysis
CIK: 1840233 CUSIP: 98422T100 ISIN: US98422T1007 LEI: - UEI: -
Secondary Listings
XLO has no secondary listings inside our databases.